Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 144807 in newly diagnosed wet age-related macular degeneration
2013-004567-30Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BI 144807 in exudative macular degeneration, sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in 1 mm central retinal thickness. Started Feb 2014; status: terminated.
02
Drugs
BI 144807
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-004567-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004567-30.